Incyte’s (INCY) “Buy” Rating Reaffirmed at Cowen and Company

Incyte Co. (NASDAQ:INCY)‘s stock had its “buy” rating reissued by investment analysts at Cowen and Company in a report released on Friday, May 5th.

The analysts wrote, “Incyte reported Q1 financials and provided a pipeline update.””

A number of other equities research analysts have also recently weighed in on INCY. BMO Capital Markets restated a “buy” rating and issued a $135.00 price objective (up previously from $122.00) on shares of Incyte in a report on Tuesday, January 10th. JMP Securities restated an “outperform” rating and issued a $130.00 price objective on shares of Incyte in a report on Wednesday, January 18th. Barclays PLC increased their price target on shares of Incyte from $105.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, January 19th. Credit Suisse Group AG started coverage on shares of Incyte in a report on Monday, January 23rd. They set an “outperform” rating and a $137.00 price target on the stock. Finally, Goldman Sachs Group Inc increased their price target on shares of Incyte from $116.00 to $149.00 and gave the company a “buy” rating in a report on Friday, January 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $139.93.

Analyst Recommendations for Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) traded up 2.04% during mid-day trading on Friday, reaching $131.43. The company’s stock had a trading volume of 3,856,544 shares. Incyte has a 52-week low of $71.75 and a 52-week high of $153.15. The stock’s market cap is $26.91 billion. The company has a 50 day moving average of $126.97 and a 200-day moving average of $119.23.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.97) by $0.01. The business had revenue of $384.08 million for the quarter, compared to analysts’ expectations of $359.19 million. Incyte had a net margin of 14.71% and a return on equity of 50.38%. The business’s revenue was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.12 earnings per share. Equities analysts forecast that Incyte will post ($0.76) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Incyte’s (INCY) “Buy” Rating Reaffirmed at Cowen and Company” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/05/20/incytes-incy-buy-rating-reiterated-at-cowen-and-company-updated.html.

In other Incyte news, Director Jean Jacques Bienaime acquired 1,000 shares of the company’s stock in a transaction on Friday, April 7th. The stock was acquired at an average cost of $139.48 per share, with a total value of $139,480.00. Following the purchase, the director now directly owns 2,177 shares of the company’s stock, valued at approximately $303,647.96. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Paul A. Friedman sold 50,000 shares of Incyte stock in a transaction on Friday, March 17th. The stock was sold at an average price of $148.72, for a total transaction of $7,436,000.00. Following the completion of the transaction, the director now directly owns 302,976 shares of the company’s stock, valued at $45,058,590.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 3,000 shares of company stock valued at $398,770 and have sold 137,968 shares valued at $19,395,245. Company insiders own 13.70% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC purchased a new stake in Incyte during the first quarter valued at about $105,000. FNY Partners Fund LP raised its stake in Incyte by 4,825.0% in the first quarter. FNY Partners Fund LP now owns 985 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 965 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Incyte by 1.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,322 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 22 shares during the last quarter. IFP Advisors Inc raised its stake in shares of Incyte by 6.8% in the first quarter. IFP Advisors Inc now owns 1,043 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 66 shares during the last quarter. Finally, Howard Hughes Medical Institute raised its stake in shares of Incyte by 42.2% in the first quarter. Howard Hughes Medical Institute now owns 1,210 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 359 shares during the last quarter. Hedge funds and other institutional investors own 92.62% of the company’s stock.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

12 Month Chart for NASDAQ:INCY

Receive News & Ratings for Incyte Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply